| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Audentes Therapeutics (BOLD) | BofA Merrill Lynch/ Cowen and Company/ Piper Jaffray | $86.25 | n.a. | |||
| Audentes Therapeutics (BOLD) | BofA Merrill Lynch/ Cowen and Company/ Piper Jaffray | $86.25 | n.a. | |||
| Bavarian Nordic A/S (BAVN) | Cowen and Company/ Piper Jaffray | $86.25 | n.a. | |||
| Clearside Biomedical (CLSD) | RBC Capital Markets/ Stifel | $57.00 | n.a. | |||
| Corvus Pharmaceuticals (CRVS) | Credit Suisse/ Cowen and Company | $115.00 | n.a. | |||
| Grupo Supervielle S.A. (TBA) | Morgan Stanley/ BofA Merrill Lynch | $100.00 | n.a. | |||
| OTG EXP (OTG ) | Morgan Stanley/ Credit Suisse/ Barclays/ BMO Capital Markets | $100.00 | n.a. | |||
| Reata Pharmaceuticals (RETA) | Citigroup/ Cowen and Company/ Piper Jaffray | $80.00 | n.a. | |||
| Spring Bank Pharmaceuticals (SBPH) | William Blair/ Wedbush PacGrow/ BTIG | $57.50 | n.a. | |||
| Syndax Pharmaceuticals (SNDX) | Morgan Stanley/ Citigroup | $86.25 | n.a. | |||
| Tabula Rasa HealthCare (TRHC) | Wells Fargo Securities/ UBS Investment Bank/ Piper Jaffray | $115.00 | n.a. | |||
| Visterra (VIST) | Leerink Partners/ Stifel | $69.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| 21st Century Oncology Holdings (ICC) | Morgan Stanley/ J.P. Morgan/ Wells Fargo Securities | 11.11 | $8.00 | $10.00 | $99.99 | n.a. |
| SurgiQuest (TBA) | Piper Jaffray/ Stifel | $75.00 | n.a. | |||
| New Terms | ||||||
| GMS (GMS) | Barclays/ Credit Suisse | $200.00 | n.a. | |||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Jan. 4, 2016 | Manager(s) | Offered | Raised | Price | 1/8/16 | Change |
| None | ||||||
